Randomized Phase II Trial of Docetaxel With or Without PSA-TRICOM Vaccine in Patients With Castrate-Resistant Metastatic Prostate Cancer.

Trial Profile

Randomized Phase II Trial of Docetaxel With or Without PSA-TRICOM Vaccine in Patients With Castrate-Resistant Metastatic Prostate Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 May 2017

At a glance

  • Drugs Rilimogene galvacirepvec (Primary) ; Rilimogene glafolivec (Primary) ; Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 May 2017 Status changed from active, no longer recruiting to completed.
    • 22 Jul 2014 Planned End Date changed from 1 Jun 2013 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
    • 07 Feb 2013 New source identified and integrated (Mayo Clinic; 10-006476).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top